Top

Clinical and Translational Oncology

Published in:

Open Access 30-08-2023 | Pityriasis Lichenoides Chronica | RESEARCH ARTICLE

Analysis of the prognostic value of uric acid on the efficacy of immunotherapy in patients with primary liver cancer

Authors: Hui Rao, Qi Wang, Xiaoli Zeng, Xuejiao Wen, Li Huang

Published in: Clinical and Translational Oncology | Issue 3/2024

Abstract

Purpose

Uric acid (UA) plays a dual role as an antioxidant and a prooxidant in patients with malignant tumors; however, the relationship between serum UA and malignancy is currently unclear. This study aims to investigate the prognostic value of serum uric acid level before immunotherapy on the efficacy of primary liver cancer (PLC) immunotherapy, which might provide a basis for optimizing the comprehensive treatment scheme.

Methods

Patients with PLC who were admitted to the First Affiliated Hospital of Gannan Medical College from January 2019 to June 2022 and underwent immunotherapy were collected retrospectively. The difference between serum UA levels in patients with PLC, the correlation between serum UA levels, and the clinical characteristics of patients with PLC were analyzed using the chi-square test, and the survival was estimated using the Kaplan–Meier analysis. To further assess the prognostic significance of UA concentrations, univariate and multivariate Cox regression analyses were performed.

Results

Ninety-nine patients were included in this study cohort. The median follow-up was 7 months (range: 1–29 months), and 76 (76.8%) of the 99 patients with PLC died as of December 31, 2022. Serum UA concentrations ranged from 105 to 670 μmol/l, with a median of 269 μmol/l. The results showed that the serum UA level of patients with PLC was higher than that of healthy subjects (P < 0.001). After subgroup analyses, only male patients with liver cancer had higher serum UA levels than healthy men (P = 0.001). The results of the Kaplan–Meier analysis showed that higher UA levels were associated with poor overall survival (OS) (P = 0.005). In univariate analysis, the OS rate of patients with elevated serum UA levels was significantly lower than the cut-off value (hazard ratio [HR]: 3.191, 95% confidence interval [CI]: 1.456–6.993, P = 0.004), with a median survival time of 151 and 312 days in the high and low serum UA groups, respectively. The results of multivariate analysis showed that the UA level was an independent prognostic factor for immunotherapy in patients with PLC (HR: 3.131, 95% CI: 1.766–5.553, P < 0.001).

Conclusions

The serum UA level is a reliable biomarker for predicting the prognosis of patients undergoing immunotherapy for PLC, and might provide a basis for the individualized treatment of these patients. Dynamic monitoring of the serum UA level may compensate for the deficiency of the current liver cancer staging system.

Medical Administration of the National Health Commission of the People’s Republic of China. Code of practice for the diagnosis and treatment of primary liver cancer (2019 edition). Electron J Integr Oncol Ther. 2020;6:55-84

Buder-Bakhaya K, Hassel JC. Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-a review from the melanoma perspective and beyond. Front Immunol. 2018;9:1474.PubMedPubMedCentralCrossRef

FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AML, et al. American college of rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020;72:879–95.PubMedCrossRef

Battelli MG, Bortolotti M, Polito L, Bolognesi A. The role of xanthine oxidoreductase and uric acid in metabolic syndrome. Biochim Biophys Acta Mol Basis Dis. 2018;1864:2557–65.PubMedCrossRef

Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med. 2012;1:16.PubMedPubMedCentralCrossRef

Dai XY, He QS, Jing Z, Yuan JQ. Serum uric acid levels and risk of kidney cancer incidence and mortality: a prospective cohort study. Cancer Med. 2020;9:5655–61.PubMedPubMedCentralCrossRef

Yiu A, Hemelrijck MV, Garmo H, Holmberg L, Malmström H, Lambe M, et al. Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study. Oncotarget. 2016;8:42332–42.CrossRef

Yan S, Zhang P, Xu W, Liu Y, Wang B, Jiang T, et al. Serum uric acid increases risk of cancer incidence and mortality: a systematic review and meta-analysis. Mediators Inflamm. 2015;2015: 764250.PubMedPubMedCentralCrossRef

Kobylecki CJ, Afzal S, Nordestgaard BG. Plasma urate, cancer incidence, and all-cause mortality: a mendelian randomization study. Clin Chem. 2017;63:1151–60.PubMedCrossRef

10.

Nath SD, Voruganti VS, Arar NH, Thameem F, Lopez-Alvarenga JC, Bauer R, et al. Genome scan for determinants of serum uric acid variability. J Am Soc Nephrol. 2007;18:3156–63.PubMedCrossRef

11.

Englund C, Loren CE, Grabbe C, Varshney GK, Deleuil F, Hallberg B, et al. Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion. Nature. 2003;425:512–6.PubMedCrossRefADS

12.

Shi Y, Zheng W, Rock KL. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci. 2000;97:14590–5.PubMedPubMedCentralCrossRefADS

13.

Liu Y, Yan W, Tohme S, Chen M, Fu Y, Tian D, et al. Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J Hepatol. 2015;63:114–21.PubMedPubMedCentralCrossRef

14.

Jenkins RB. When are airgun pellets better left alone? The Lancet. 1985;325:1213–4.CrossRef

15.

Lv Y, Patel N, Zhang HJ. The progress of non-alcoholic fatty liver disease as the risk of liver metastasis in colorectal cancer. Expert Rev Gastroenterol Hepatol. 2019;13:1169–80.PubMedCrossRef

16.

Lin CC, Yin MC. B vitamins deficiency and decreased anti-oxidative state in patients with liver cancer. Eur J Nutr. 2007;46:293–9.PubMedCrossRef

17.

Panis C, Victorino VJ, Herrera AC, Freitas LF, De Rossi T, Campos FC, et al. Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. Breast Cancer Res Treat. 2012;133:881–8.PubMedCrossRef

18.

Yuan C, Xu XH, Wang XL, Xu L, Chen Z, Li YQ. Relationship between serum uric acid and metastatic and nonmetastatic rectal cancer patients with undergoing no chemotherapy. Medicine (Baltimore). 2016;95: e5463.PubMedCrossRef

19.

Campion E, Glynn RJ, DeLabry LO. Risks and consequences in the normative aging study. Am J Med. 1987;82:421–6.PubMedCrossRef

20.

Arora S, Chawla R, Tayal D, Gupta VK, Sohi JS, Mallika V. Biochemical mar kers of liver and kidney function are influenced by thyroid function—A case-con trolled follow up study in Indian hypothyroid subjects. Indian J Clin Biochem. 2009;24:370–4.PubMedPubMedCentralCrossRef

21.

Horsfall LJ, Nazareth I, Petersen I. Serum uric acid and the risk of respiratory disease: a population-based cohort study. Thorax. 2014;69:1021–6.PubMedCrossRef

22.

Wu CY, Hu HY, Chou YJ, Huang N, Chou YC, Lee MS, et al. High serum uric acid levels are associated with all-cause and cardiovascular, but not cancer, mortality in elderly adults. J Am Geriatr Soc. 2015;63:1829–36.PubMedCrossRef

23.

Deng Z, Gu Y, Hou X, Zhang L, Bao Y, Hu C, et al. Association between uric acid, cancer incidence and mortality in patients with type 2 diabetes: Shanghai diabetes registry study. Diabetes Metab Res Rev. 2016;32:325–32.PubMedCrossRef

24.

Yang J, Wang Y, Zhao Q, Zhang X, Wang X, Qin X, et al. Association of serum uric acid with increased risk of cancer among hypertensive Chinese. Int J Cancer. 2017;141:112–20.PubMedCrossRef

25.

Yamauchi T, Negoro E, Lee S, Takai M, Matsuda Y, Takagi K, et al. A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res. 2013;33:3947–51.PubMed

26.

Prochazka KT, Melchardt T, Posch F, Schlick K, Deutsch A, Beham-Schmid C, et al. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients. Br J Cancer. 2016;115:1264–72.PubMedPubMedCentralCrossRef

27.

Tanriverdi O, Cokmert S, Oktay E, Pilanci KN, Menekse S, Kocar M, et al. Prognostic significance of the baseline serum uric acid level in non-small cell lung cancer patients treated with first-line chemotherapy: a study of the turkish descriptive oncological researches group. Med Oncol. 2014;31:217.PubMedCrossRef

28.

Baey C, Yang J, Ronchese F, Harper JL. Hyperuricaemic UrahPlt2/Plt2 mice show altered T cell proliferation and defective tumor immunity after local immunotherapy with Poly I:C. PLoS ONE. 2018;13: e0206827.PubMedPubMedCentralCrossRef

29.

Mantovani A, Bussolino F, Dejana E. Cytokine regulation of endothelial cell function. FASEB J. 1992;6:2591–9.PubMedCrossRef

30.

Xu X, Rao GS, Groh V, Spies T, Gattuso P, Kaufman HL, et al. Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer. 2011;11:194.PubMedPubMedCentralCrossRef

31.

Dziaman T, Banaszkiewicz Z, Roszkowski K, Gackowski D, Wisniewska E, Rozalski R, et al. 8-Oxo-7,8-dihydroguanine and uric acid as efficient predictors of survival in colon cancer patients. Int J Cancer. 2014;134:376–83.PubMedCrossRef

32.

Shin HS, Lee HR, Lee DC, Shim JY, Cho KH, Suh SY. Uric acid as a prognostic factor for survival time: a prospective cohort study of terminally ill cancer patients. J Pain Symptom Manage. 2006;31:493–501.PubMedCrossRef

33.

Hammarsten J, Damber JE, Peeker R, Mellstrom D, Hogstedt B. A higher prediagnostic insulin level is a prospective risk factor for incident prostate cancer. Cancer Epidemiol. 2010;34:574–9.PubMedCrossRef

34.

Akinwunmi B, Vitonis AF, Titus L, Terry KL, Cramer DW. Statin therapy and association with ovarian cancer risk in the New England case control (NEC) study. Int J Cancer. 2019;144:991–1000.PubMedCrossRef

35.

Hua H, Zhang H, Kong Q, Wang J, Jiang Y. Complex roles of the old drug aspirin in cancer chemoprevention and therapy. Med Res Rev. 2019;39:114–45.PubMedCrossRef

36.

Risinger AL, Giles FJ, Mooberry SL. Microtubule dynamics as a target in oncology. Cancer Treat Rev. 2009;35:255–61.PubMedCrossRef

37.

Kumar A, Sharma PR, Mondhe DM. Potential anticancer role of colchicine-based derivatives: an overview. Anticancer Drugs. 2017;28:250–62.PubMedCrossRef

38.

Fong A, Durkin A, Lee H. The potential of combining tubulin-targeting anticancer therapeutics and immune therapy. Int J Mol Sci. 2019;20:586.PubMedPubMedCentralCrossRef

39.

Wang F, Wang C, Liu Y, Lan W, Han H, Wang R, et al. Colchicine selective interaction with oncogene RET G-quadruplex revealed by NMR. Chem Commun (Camb). 2020;56:2099–102.PubMedCrossRef

40.

AbouAitah K, Hassan HA, Swiderska-Sroda A, Gohar L, Shaker OG, Wojnarowicz J, et al. Targeted nano-drug delivery of colchicine against colon cancer cells by means of mesoporous silica nanoparticles. Cancers (Basel). 2020;12:144.PubMedCrossRef

41.

Mendonsa AM, VanSaun MN, Ustione A, Piston DW, Fingleton BM, Gorden DL. Host and tumor derived MMP13 regulate extravasation and establishment of colorectal metastases in the liver. Mol Cancer. 2015;14:49.PubMedPubMedCentralCrossRef

42.

Kondo T, Okabayashi K, Hasegawa H, Tsuruta M, Shigeta K, Kitagawa Y. The impact of hepatic fibrosis on the incidence of liver metastasis from colorectal cancer. Br J Cancer. 2016;115:34–9.PubMedPubMedCentralCrossRef

43.

Wan X, Xu C, Lin Y, Lu C, Li D, Sang J, et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64:925–32.PubMedCrossRef

44.

Andrade-Oliveira V, Foresto-Neto O, Watanabe IKM, Zatz R, Camara NOS. Inflammation in renal diseases: new and old players. Front Pharmacol. 2019;10:1192.PubMedPubMedCentralCrossRef

45.

Nishikawa T, Nagata N, Shimakami T, Shirakura T, Matsui C, Ni Y, et al. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice. Sci Rep. 2020;10:815.PubMedPubMedCentralCrossRefADS

Title: Analysis of the prognostic value of uric acid on the efficacy of immunotherapy in patients with primary liver cancer
Authors: Hui Rao
Qi Wang
Xiaoli Zeng
Xuejiao Wen
Li Huang
Publication date: 30-08-2023
Publisher: Springer International Publishing
Keywords: Pityriasis Lichenoides Chronica
Biomarkers
Published in: Clinical and Translational Oncology / Issue 3/2024
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-023-03314-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2024

Pattern of practice of re-irradiation for ipsilateral breast tumor recurrence in Italy: a survey by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)

Prognostic value of POD18 combined with improved IELSG in primary central nervous system lymphoma

Difficulties on the access to innovative targeted therapies for lung cancer in Spain

Impact of bone metastasis on the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Outcomes with atezolizumab in metastatic urothelial cancer: real-world data from a single institution

MMP11 and MMP17 are potential biomarkers for uterine corpus endometrial carcinoma prognosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer